YM758
Based on 1 Customer Validation
YM758 is a "funny" If current channel (If channel) inhibitor.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 312752-85-5
- Formula: C26H32FN3O4
- Molecular Weight:469.55
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
If channel[1]
The inhibitory effect of YM758 on [3H]MPP uptake via human/rat organic cation transporters (hOCT1/rOct1) is investigated. YM758 inhibits rOct1- and hOCT1-mediated [3H]MPP uptake in a concentration-dependent manner with IC50 values of 23.8 and 40.5 μM, respectively. The IC50 value of YM758 for [14C]Metformin uptake via rOct1 may be estimated below 10 μM in the same way, whereas that is much smaller than that for [3H]MPP uptake. In addition, the inhibitory effect of YM758 on [3H]E217βG uptake via OATP1B1 and OATP1B3 is investigated. YM758 inhibits OATP1B1-mediated [3H]E217βG uptake in a concentration-dependent manner with a IC50 value of 13.0 μM. YM758 has no inhibitory effect on OATP1B3-mediated [3H]E217βG uptake[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 312752-85-5
-
Appearance Solid
-
Molecular Weight 469.55
-
Formula C26H32FN3O4
-
Color White to off-white
-
SMILES
O=C([C@H]1CN(CCC1)CCNC(C2=CC=C(F)C=C2)=O)N3CC4=CC(OC)=C(OC)C=C4CC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (212.97 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
Transporter-expressing or vector-transfected HEK293 cells are grown in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin (v/v) and 100 μg/mL Zeocin at 37°C in an atmosphere of 5% CO2 and 95% humidity. The cells are subcultured in a medium containing 0.05% trypsin-EDTA solution. Cells are then seeded in poly-D-lysine-coated 12-well plates at a density of 1.2×105 cells/well. For the transport study, the cell culture medium is replaced with culture medium supplemented with 5 mM sodium-butyrate for 24 h before the transport assay to induce the expression level of hOCT1, rOct1, OATP1B1, and OATP1B3. The transport study is performed. Uptake is initiated by adding Krebs-Henseleit buffer containing radiolabeled substrates (0.6 nM [3H]MPP, 10 μM[14C]Metformin, 20 nM [3H]E217βG, or 10 μM [14C]YM758) after the cells have been washed twice and preincubated with Krebs-Henseleit buffer at 37°C for 15 min. In the concentration-dependent uptake and/or inhibition studies, the cells are incubated further in the presence of YM758 (1-1000 μM). The Krebs-Henseleit buffer consists of 2.0 mg/mL D-glucose, 0.141 mg/mL Magnesium sulfate, 0.16 mg/mL Potassium phosphate monobasic, 0.35 mg/mL Potassium chloride, 6.9 mg/mL Sodium chloride, 0.373 mg/mL Calcium chloride dihydrate, 1.5 mg/mL HEPES, and 2.1 mg/mL Sodium bicarbonate. The pH of this solution is adjusted to 7.4 with Sodium hydroxide. The uptake is terminated at the designated time by adding ice-cold Krebs-Henseleit buffer after removing the incubation buffer. The cells then are washed twice with 1 mL of ice-cold Krebs-Henseleit buffer, solubilized in 0.5 mL of 1.0 M Sodium hydroxide, and kept overnight at 4°C. Aliquots (0.5 mL) are transferred to scintillation vials after adding 0.25 mL of 2.0 M hydrochloric acid. The radioactivity associated with the cells and incubation buffer is measured in a liquid scintillation counter after adding 5 mL of scintillation fluid to the scintillation vials. The remaining cell lysate is used to determine the protein concentration by the method of Lowry, with bovine serum albumin as the standard[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Beagle[2]
Four male beagles (11.0-15.0 kg) are used for the intravenous administration study. Heart rate (HR) (beats/min) is determined by doubling the number of the QRS complexes on the ECG recorded for 30 s. First, HR is measured at rest and just after initiation of tachycardia induced by intravenous Isoproterenol (0.1 μg/kg) administration, and then YM758, which is dissolved in saline, is intravenously administered at doses of 0.03, 0.1, and 0.3 mg/kg. At 0.1, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, and 24 h after the YM758 administration, HR is measured just after intravenous isoproterenol (0.1 μg/kg) to induce tachycardia, following the measurement of resting HR at each designated point. This is followed by a minimum 1-week washout period between each study period. Blood samples (approximately 3.0 mL) are withdrawn from the vein using a heparin-treated syringe, and the electrocardiogram (ECG) is recorded at the times designated (0.1, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, and 24 h after administration). Plasma is obtained by centrifugation of the blood samples at 1870g for 15 min at 4°C and then stored at -20°C until determination of the YM758 concentrations[2].
Rats[3]
Male Long-Evans rats (7 weeks) and Sprague-Dawley rats (9 weeks) are used. 3 mg/2.57 MBq/10 mL/kg is given to rats orally by gavage using a syringe with a gastric tube.The nonalbino rats are sacrificed by ether overdose 4 and 24 h after a single oral administration of 3 mg/kg 14C-YM758. The fur is then rapidly clipped off, and the nasal cavity and anus are filled with 4% carboxymethylcellulose-Na. The carcass is frozen in a dry ice-acetone mixture, and the forelimbs, hind limbs, and tail are surgically removed[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Umehara K, et al. Hepatic uptake and excretion of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans. Drug Metab Dispos. 2008 Jun;36(6):1030-8. [Content Brief]
[2]. Umehara K, et al. Relationship between exposure of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a "funny" if current channel inhibitor, and heart rate reduction in tachycardia-induced beagle dogs. Drug Metab Dispos. 2009 Jul;37(7):1427-33. [Content Brief]
[3]. Umehara K, et al. Investigation of long-term retention of unchanged (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide, a novel "funny" If current channel inhibitor, and its metabolites in the eyeball and thoracic aorta of rats. Drug Metab Dispos. 2009 Nov;37(11):2137-44. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1297 mL | 10.6485 mL | 21.2970 mL | 53.2425 mL |
| 5 mM | 0.4259 mL | 2.1297 mL | 4.2594 mL | 10.6485 mL | |
| 10 mM | 0.2130 mL | 1.0648 mL | 2.1297 mL | 5.3242 mL | |
| 15 mM | 0.1420 mL | 0.7099 mL | 1.4198 mL | 3.5495 mL | |
| 20 mM | 0.1065 mL | 0.5324 mL | 1.0648 mL | 2.6621 mL | |
| 25 mM | 0.0852 mL | 0.4259 mL | 0.8519 mL | 2.1297 mL | |
| 30 mM | 0.0710 mL | 0.3549 mL | 0.7099 mL | 1.7747 mL | |
| 40 mM | 0.0532 mL | 0.2662 mL | 0.5324 mL | 1.3311 mL | |
| 50 mM | 0.0426 mL | 0.2130 mL | 0.4259 mL | 1.0648 mL | |
| 60 mM | 0.0355 mL | 0.1775 mL | 0.3549 mL | 0.8874 mL | |
| 80 mM | 0.0266 mL | 0.1331 mL | 0.2662 mL | 0.6655 mL | |
| 100 mM | 0.0213 mL | 0.1065 mL | 0.2130 mL | 0.5324 mL |